Core Insights - Ascendis Pharma A/S will present new data on its hypoparathyroidism, achondroplasia, and growth hormone deficiency programs at the ESPE & ESE 2025 congress in Copenhagen from May 10-13, 2025 [1][2] Hypoparathyroidism - The company will showcase 4-year efficacy and safety data from the Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) in adults with chronic hypoparathyroidism [2][4] - Presentations will include a retrospective matched cohort study using real-world data from England to estimate the risk of chronic kidney disease progression in chronic hypoparathyroidism [4][6] Achondroplasia - Ascendis will present Week 52 growth and bone morphometry data from the pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children with achondroplasia [2][4] - The congress will feature discussions on assessing health-related quality of life (HRQoL) in achondroplasia across the life course [4][6] Growth Hormone Deficiency - The company will present results from the Phase 3 foresiGHt Trial supporting the efficacy and safety of once-weekly lonapegsomatropin in adults with growth hormone deficiency [2][6] - The presentations will highlight the importance of growth hormone in maintaining normal body composition and cardiometabolic health throughout adulthood [9] Company Overview - Ascendis Pharma is a global biopharmaceutical company focused on innovative therapies using its TransCon technology platform to address unmet medical needs [10] - The company is headquartered in Copenhagen, Denmark, with additional facilities in Europe and the United States [10]

Group 1 - The article expresses a beneficial long position in the shares of ASND, indicating a positive outlook on the company's stock performance [1] - The author emphasizes that the opinions presented are personal and not influenced by any business relationships with the mentioned companies [1] - There is a clear distinction made that the commentary does not constitute personalized investment advice, urging readers to conduct their own due diligence [2] Group 2 - The article highlights that past performance is not indicative of future results, which is a common disclaimer in investment discussions [3] - It is noted that the views expressed may not reflect those of Seeking Alpha as a whole, indicating a diversity of opinions among analysts [3] - The article clarifies that Seeking Alpha does not act as a licensed securities dealer or investment adviser, reinforcing the need for independent research by investors [3]

Core Insights - Ascendis Pharma has submitted a New Drug Application (NDA) to the FDA for TransCon CNP, aimed at treating children with achondroplasia, supported by data from three clinical trials and up to three years of open-label extension data [1][2] - The company plans to submit a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in Q3 2025 [3] Group 1: Clinical Data and Benefits - Clinical data indicates that TransCon CNP not only increases growth velocity but also reduces health-related burdens, enhances muscle function, and corrects leg bowing in most treated children [3] - The treatment is administered once weekly and has a safety and tolerability profile comparable to placebo, positioning it as a potential best-in-class treatment for achondroplasia [3] Group 2: Achondroplasia Overview - Achondroplasia is a rare genetic condition affecting over 250,000 people globally, leading to various complications beyond skeletal dysplasia, including muscular, neurological, and cardiorespiratory issues [4] - Complications can include spinal deformities, impaired muscle strength, and chronic pain, significantly impacting quality of life and requiring multiple surgeries [4] Group 3: Company Background - Ascendis Pharma is a global biopharmaceutical company focused on innovative therapies using its TransCon technology platform to address unmet medical needs [5] - The company is headquartered in Copenhagen, Denmark, with additional facilities in Europe and the United States [5]

将投中网设为"星标⭐"，第一时间收获最新推送 瑞凯以长期主义强势看多中国生物医药行业。 来源丨投中网 中国生长激素市场规模2023年达116亿元，预计2030年将增长至286亿元，其中长效剂型（每周注射 一次）占比将超70%。 在这个百亿级大市场中，长春高新旗下的金赛药业几乎一家独大，占据超过80%的市场份额，手握一 系列大单品（尤其长效剂型目前只有金赛增唯一在售），长春高新一度市值超过2000亿人民币，被 称为"东北药茅"。 时至今日，一位颇有潜力的破局者——维昇药业（VISEN Pharmaceuticals）杀入，核心产品"隆培促 生长素（lonapegsomatropin）"，采用每周一次的长效给药方案，相较于传统短效剂型需每日注射， 极大提升了患者依从性，临床数据显示在安全性相当的前提下，疗效均优于现有短效剂型，而且25 周和52周的数据均优于长春高新旗下金赛。 更重要的是，该产品在美国和欧洲市场的名称是Skytrofa，已由维昇药业的母公司Ascendis Pharma （ASND.US）成功商业化，据Evaluate Pharm预测，到2026年销售额将达到15亿美元。Ascendis凭 此在纳 ...